LIP
VRDN icon

Lighthouse Investment Partners’s Viridian Therapeutics VRDN Stock Holding History

Lighthouse Investment Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Buy
+120,000
New +$1.93M 0.06% 356
2024
Q2 		– Sell
-28,406
Closed -$497K – 550
2024
Q1 		$497K Buy
+28,406
New +$551K 0.02% 331

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Lighthouse Investment Partners's VRDN Position: Q2 2026 in Review

Lighthouse Investment Partners opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 120,000 shares worth $2.2M. The stake represents 0.06% of the portfolio and ranks #356 among its holdings. This is a return to the name: Lighthouse Investment Partners previously reported a position in VRDN as recently as Q1 2024.

Lighthouse Investment Partners first reported a position in VRDN in Q1 2024 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Lighthouse Investment Partners held 120,000 shares of Viridian Therapeutics worth $2.2M as of Q2 2026.
  • Viridian Therapeutics was a new Lighthouse Investment Partners position in Q2 2026.
  • Viridian Therapeutics made up 0.06% of Lighthouse Investment Partners's portfolio in Q2 2026, its #356 holding.
  • Lighthouse Investment Partners first reported a position in Viridian Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Lighthouse Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.